Follow-on Order from Government of Ontario Procurement Authorities MISSISSAUGA, CANADA, December 24, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces receipt of a follow-on order of C$ 4.7 million for its viral transport medium (generically known as “VTM” and branded “DxTM™” by Microbix). DxTM is a sample-collection device that is essential for PCR-based testing for viruses that cause COVID-19 disease. This further order has been made by a procurement authority representing the Province of...

Record Sales of $18.6 million, Record Net Earnings of $3.2 million MISSISSAUGA, December 23, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for its year and fourth quarter ended September 30, 2021 (“2021” and “Q4”), with record sales and earnings, plus progress upon its strategic goal of increasing the proportion of revenues derived from medical devices. Management Discussion 2021 revenues were up 77% from 2020, achieving a record level of $18.6 million as Microbix continues to...

Helping Ensure Workflow Accuracy of Tests for COVID, Flu A, Flu B, and RSV MISSISSAUGA, CANADA, December 20, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces the expansion of its portfolio of Quality Assessment Products (“QAPs™”) to include single-unit swab-formatted controls that simultaneously support PCR tests for SARS-CoV-2 (“COVID”), Influenza A (“Flu A”), Influenza B (“Flu B”), and Respiratory Syncytial Virus (“RSV”), four of the most-common causes of viral infectious respiratory illness...

Helping Ensure Workflow Accuracy of PCR Tests for COVID “Variants of Concern” MISSISSAUGA, CANADA, November 17, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces the expansion of its portfolio of Quality Assessment Products (“QAPs™”) to include controls that support PCR tests for each of the four major variants of concern (“VOCs”) of the SARS-CoV-2 virus that is the cause of the COVID-19 pandemic. Specifically, Microbix has developed, and is now commercializing, In-Vitro Diagnostic (“IVD”)...

Further Capital to Assist with Increasing Capacity and Efficiency MISSISSAUGA, CANADA, October 27, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has received C$ 2.7 million from the partial exercise of two series of expiring share purchase warrants. The first series of such warrants were issued in connection with a private placement undertaken in October, 2015, and had an exercise price of C$ 0.55 and a five-year term. The original term of these warrants was extended by one year, as...

$1.3 million balance repaid, improving cash flow and resulting in non-cash charge MISSISSAUGA, CANADA, October 4, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has completed the early repayment of a debenture series on which it owed C$ 1.3 million and was paying an interest rate of 9.0%. This debenture was issued on January 31, 2014 for an outstanding amount C$ 2.0 million and was subsequently being repaid via quarterly payments of interest and principal of $61,100. At October 1,...

QAPs to Support Testing for COVID Viral Variants MISSISSAUGA, CANADA, September 27, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has been invited to present about the performance of its COVID-19 test quality assessment products (QAPs™) at “AACC” the annual scientific meeting & clinical laboratory exposition of the American Association of Clinical Chemistry, taking place in live and virtual formats from Atlanta, GA, September 26-30, 2021. The abstract poster presentation is...

Meetings with Growth-Oriented Investors, September 24-26, 2021 MISSISSAUGA, September 23, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter,  announces that it will be presenting to investors at the Muskoka Capital Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Rosseau Muskoka, in Minett, ON, September 24-26, 2021. Microbix’s CEO, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company investors during the formal portion of the...

Trading Upgrade to OTCQX Best Market and Torrey Hills Capital Engaged MISSISSAUGA, ON, August 3, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has undertaken two actions to improve its profile with United States (U.S.) based investors and to improve its trading liquidity in that market; (i) effective today, achieving qualification to trade on the OTCQX® Best Market under the symbol MBXBF, and (ii) engaged the California-based firm Torrey Hills Capital for U.S. directed investor...

Two Abstracts Reporting on Cross-Platform Utility of Antigen & Serological QAPs™ MISSISSAUGA, CANADA, July 8, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has been invited to present about the performance of its COVID-19 test quality assessment products (QAPs™) at “ECCMID 2021” the 31st annual congress organized by the European Society of Clinical Microbiology and Infectious Diseases, taking place in virtual format July 9-12, 2021. The first abstract poster presentation is...

Appointment of Thomas Scientific as U.S. Distributor MISSISSAUGA, July 7, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the appointment of Thomas Scientific LLC as distributor of Microbix’s quality assessment products (QAPs™) for the United States. Under an agreement between the parties, Thomas Scientific has been appointed as the second distributor of Microbix’s QAPs in the United States. Thomas Scientific will thereby provide customer service, sales and marketing, distribution, and...

Leasing and Equipping 10,000 Square Foot Building Adjacent to Current Sites MISSISSAUGA, June 3, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has secured a third manufacturing site in Mississauga, Ontario, by way of a long-term lease agreement for a property adjacent to its two current sites. Specifically, Microbix has secured a multi-year lease to a 10,000 square foot industrial building located at 275 Watline Avenue – Immediately next to its owned biologicals facility that is...

Appointment of SDT Molecular of Singapore MISSISSAUGA, May 31, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the appointment of SDT Molecular Pte Ltd (SDT) as distributor of Microbix’s quality assessment products (QAPs™) for four Asia-Pacific territories. Under an agreement between the parties, SDT has been appointed as distributor of Microbix’s QAPs for Hong Kong, Indonesia, Malaysia, and its home base of Singapore. SDT will thereby provide customer service, sales and marketing,...

$6.9 Million of Gross Proceeds Received - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES - MISSISSAUGA, May 19, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces it has closed its previously-announced bought-deal public offering (the “Offering”) and concurrent private placement (the “Placement”). The co-lead bookrunners and underwriters of the Offering, iA Private Wealth Inc. and  Bloom Burton Securities Inc. (the “Underwriters”), have purchased the full Offering,...

Record Q2 Sales of $4.35 million, Record Net Earnings of $0.8 million MISSISSAUGA, May 13, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for its second quarter and first half of fiscal 2021 ending March 31, 2021 (“Q2” and “H1”), with record sales and earnings, plus progress upon its strategic goals. Management Discussion Q2 revenues were up 51% from 2020, achieving a record level of $4.35 million as Microbix continues to emphasize its sales of innovative, proprietary, and branded...

$5.0 Million Bought-Deal Public Offering and $1.0 Million Private Placement - NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES - MISSISSAUGA, April 28, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce it has entered into an agreement with iA Private Wealth Inc. and Bloom Burton Securities Inc. (the "Underwriters"), who will act as co-bookrunners and co-lead underwriters, pursuant to which the Underwriters have agreed to purchase, on a bought deal basis,...

Focus on Diagnostics and Controls for Anti-Microbial Resistant Infections MISSISSAUGA, CANADA and EVELEIGH, AUSTRALIA April 26, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and SpeeDx Pty. Ltd. (SpeedDx), a developer of innovative molecular diagnostics solutions, are pleased to announce the formation of a collaboration under which Microbix will be exclusive developer of Quality Assessment Products (QAPs™) to facilitate the registration and commercialization of SpeeDx diagnostic assays. The...

An Initial Order From Government Of Ontario Procurement Authorities MISSISSAUGA, April 23, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that it has received an initial order of CDN$ 4.25 million for its viral transport medium (generically known as “VTM” and branded as “DxTM™” by Microbix). DxTM is a test sample-collection device that is essential for PCR-testing for the virus causing COVID-19 disease. This initial order  has been made by a procurement authority representing the Province of...

Virtual Healthcare Investor Conference on April 20 & 21 MISSISSAUGA, April 19, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that its CEO, Cameron Groome, has been invited to present at the 2021 Bloom Burton & Co. Healthcare Investor Conference, being held virtually from Toronto, Ontario, Canada, on April 20 and 21, 2021. Microbix’s CEO will speak to its latest corporate presentation at 2:30 PM ET, on Wednesday, April 21 as a part of Track 3 of the Conference.  Microbix will also...

MISSISSAUGA, March 31, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF)( “Microbix®” or the Company”), a life sciences innovator and exporter, announces the voting results from the Annual and Special Meeting of Shareholders of the Company (the “Meeting”) which was held on March 30, 2021. At the Meeting, 43.29% of the issued and outstanding shares were represented. Shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolutions that were voted upon are set out in the Management Information Circular (the “Circular”)...

Focus on Supporting Canadian Labs with Variant-related Assays and QAPs MISSISSAUGA & TORONTO, March 15, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and Seegene Canada Inc. (Seegene®), a  provider of leading-edge molecular diagnostics assays and instruments (made by Seegene Inc. of Seoul, Korea), are pleased to announce   a collaboration under which Seegene will distribute and recommend Microbix’s new COVID-variant Quality Assessment Products (QAPs™) to  monitor the  workflow accuracy  of...

REDxFLOQ SARS-CoV-2 Antigen as IVD Controls in Canada, the EU, and the U.S. MISSISSAUGA, March 11, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the availability of more of its Quality Assessment Products (QAPs™) as In-Vitro Diagnostic “IVD” Controls – to monitor the workflow accuracy of antigen-based tests for the virus causing COVID-19 disease in Canada, the EU, and the United States. Antigen-based tests look for intact or fragmented virus within a patient sample, which can be taken and...

Using Shareholder-Approved Plan to Incentivize and Retain MISSISSAUGA, February 18, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. Details of the Option Issuance In consultation with the CEO, CFO, and COO, Microbix’s Board of Directors has approved the issuance of...

Oneworld Accuracy as a Non-Exclusive Distributor for Africa and Other Territories MISSISSAUGA, February 16, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces an agreement (Agreement) with Oneworld Accuracy Inc. (1WA) to distribute Microbix’s Quality Assessment Products (QAPs™) on a non-exclusive basis across the continent of Africa, in Canada, and in the United States. Under the Agreement, 1WA will provide physical distribution, sales and marketing, and technical support for Microbix’s growing...

Record Q1 Sales, With Nearly 3,600% Year-Over-Year QAPs Growth MISSISSAUGA, February 11, 2021 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, reports results for the first quarter of its fiscal 2021, the three-months ended December 31, 2020 ("Q1"), with record sales and continued progress upon its strategic goals. Management Discussion Q1 results are demonstrating the diagnostics sector uptake of Microbix's innovative, proprietary, and branded test quality assessment products ("QAPs™"). Overall QAPs sales...

Initial Production of 50,000 Vials Entirely Sold MISSISSAUGA, February 9, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce material first sales of its viral transport medium (generically known as VTM and branded as DxTM™) that supports Canadian RT-PCR (molecular) testing for the virus causing COVID-19 disease. First sales of 50,000 vials (approximately one lot) have now been made to a private-market client at Microbix’s targeted pricing for this newly-available product. At the...

Initial Capacity of 50,000 Vials/Week under Health Canada Regulation MISSISSAUGA, January 28, 2021 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce the commercial availability of its viral transport medium (VTM) to support Canadian RT-PCR (molecular) testing for the virus causing COVID-19 disease. At the request of the Government of Ontario, Microbix has created a secure and locally-based supply of high-quality VTM, any shortage of which limits capacity for COVID-19 testing. Microbix...

For FLOQ devices & QAPs Co-branding, IP licensing, Co-marketing, Purchase, and Supply MISSISSAUGA, CANADA and BRESCIA, ITALY, December 21, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, and Copan Italia S.p.A. (Copan®), the global leader in specimen collection technologies, announce their execution of a strategic agreement (Agreement) in relation to Microbix’s quality assessement products (QAPs™) and Copan’s flocked devices (FLOQ®). The Agreement between Microbix and Copan expands upon an existing...

Full-Year Sales of $10.5 Million, QAPs Sales Grow by 41%   MISSISSAUGA, December 18, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its 2020 fiscal year ("2020") and fourth quarter ("Q4") ended September 30, 2020, with continued progress toward its operational goals. Management Discussion 2020 did not achieve the financial targets we had set-out at the start of the year-...

Reporting on Test-Workflow Controls for Important Sexually-Transmitted Infections MISSISSAUGA, CANADA, December 15, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces it has been invited to present about the performance of two types of its test-workflow Quality Assessment Products (QAPs™) at the 2020 virtual Scientific Meeting and Clinical Lab Expo of the American Association of Clinical Chemistry (AACC) taking place December 13-17, 2020. The first abstract presentation is titled “Novel...

Appointment of Anthony J. Giovinazzo, Accomplished Life Sciences Leader MISSISSAUGA, CANADA, December 7, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces that Mr. Anthony J. Giovinazzo, an accomplished leader in the international life sciences industry, has joined its Board of Directors. Mr. Giovinazzo joined the Board of Directors effective today, and was also appointed as a member of the Audit Committee and the Human Resources, Compensation & Governance Committee. Mr. Giovinazzo has over...

Sales Of QAPs™ Kits To Help Qualify Multi-Pathogen Respiratory Test Systems MISSISSAUGA, CANADA, October 29, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces the availability and initial material sales of “onboarding” kits of its quality assessment products (QAPs™), designed to help testing sites with the successful installation and qualification of multi-pathogen respiratory testing systems. Branded as “ONBOARDx™,” these QAPs kits are “RUO” classed and intended to assist labs with confirming...

QAPs™ To Support Accuracy Of COVID-19 Antigen-Test Workflows MISSISSAUGA, CANADA, October 20, 2020 - Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, announces its creation,  external verification, initial sales, and first shipments of a new class of quality assessment products (QAPs™) to help implement or ensure workflow accuracy of antigen-based tests for the virus causing COVID-19 disease. Antigen-based tests look for intact or fragmented virus within a patient sample, which can be taken and analyzed at the...

Grant Of $1.45 Million For Ontario-Based Production Of Critical Test Reagents MISSISSAUGA, October 13, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), a life sciences innovator and exporter, is pleased to announce the execution of a grant agreement with the Ontario Together Fund (OTF) of the Ministry of Economic Development, Job Creation and Trade (MEDJCT). The Honorable Vic Fedeli, Minister of MEDJCT, Minister responsible for OTF, and Member of Provincial Parliament for Nipissing, has approved an OTF grant of $1.45 million to cover 50% of...

William J. Gastle Retiring, Martin Marino Nominated To Become Independent Chairman MISSISSAUGA, CANADA, September 15, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, announces that its founder and Executive Chairman William J. (Bill) Gastle has elected to retire effective October 15, 2020, and that Martin Marino has been nominated to become the Independent Chairman of its Board of Directors. Bill Gastle, a virologist by training, founded Microbix in 1984 and took it public in 1990. The...

Enables Use of COVID-19 and HPV Products by Australian Clinical Labs MISSISSAUGA, CANADA, September 10, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, is pleased to announce attainment of Australian Therapeutic Goods Administration (TGA) registration for its COVID-19 and high-risk HPV quality assessment products (QAPs™) – TGA registration of these REDx™ Controls & REDx™FLOQ® products by Microbix’s distributor, R-Biopharm, enables it to offer these workflow controls to Australian...

Year-Over-Year QAPs Sales Growth of 141% for Q3 MISSISSAUGA, August 14, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, reports results for its third quarter and year to date fiscal 2020 (Q3 and YTD) ended June 30, 2020, with an increase of 141% in sales of Quality Assessment products (QAPs™). Management Discussion Overall, Q3 revenues were down from Q3 2019, due in part to negative pressure on antigen demand for non-COVID infectious disease testing. Specifically, lower antigen revenues were achieved...

Curious to see how we perform a COVID test? The video shows the laboratory steps involved in testing four patient samples along with one Control. The reagents and procedures are for the “CDC test” for SARS-CoV-2. Still, there is no difference in processing these patient samples from any sample evaluated for respiratory or sexually transmitted infections. The CDC test procedure is very similar to most manual molecular diagnostic tests. Most infectious disease tests are manual or semi-manual due to their low cost and versatility. These tests, like the CDC’s test,...

OTC Markets Listing and DTC Electronic Clearance Eligibility MISSISSAUGA, ON, CANADA, July 14, 2020 – Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix®), an award-winning life sciences innovator and exporter, announces that it has completed two processes to make its common shares available for U.S. investors to buy and sell; (i) the listing of its common shares on the OTCQB platform under the ticker symbol MBXBF, and (ii) approval for electronic clearance and settlements of trades by way of DTC Eligibility. The OTCQX® Best Market, OTCQB® Venture...

Enables Usage of SARS-CoV-2 Controls by Clinical Labs across Europe MISSISSAUGA, CANADA, June 5, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, is pleased to announce the attainment of European Union “CE mark” (Conformité Européene) registration for its SARS-CoV-2 quality assessment products (QAPs™) – CE mark registration enables Microbix’s network of distributors that now covers 18 EU countries to immediately begin providing these products to clinical laboratories across the EU. The Microbix...

Appointment of Medical Supply Company of Ireland MISSISSAUGA, March 24, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®),  a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces the appointment of The Medical Supply Company of Ireland (MSC) as a distributor. Under an agreement between the parties, MSC has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for the Republic of Ireland and Northern Ireland. As...

Instrument-Specific Controls to Support Rapid Tests for Viral Respiratory Pathogens MISSISSAUGA, June 1, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has been engaged to develop and supply custom quality assessment products (QAPs™) to support the registration and sales of a new point-of-care instrument and its tests for viral respiratory pathogens. Under an agreement between the parties, the companies’ technical teams are collaborating to develop custom QAPs to support submission...

Build-out to Support Tenfold Increase Now Underway MISSISSAUGA, CANADA, May 27, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has begun a build-out of its second facility that is initially intended to support a tenfold increase of production capacity for its QAPs™ quality assessment products – Which support the accuracy of clinical laboratory testing including, but not limited to, support for tests for the SARS-CoV-2 virus causing COVID-19 disease. Microbix’s current maximum QAPs...

Six Units in Ongoing Use for Foreseeable Future, Seventh Ordered MISSISSAUGA, CANADA, May 19, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has achieved full utilization of the six bioreactor units it installed for manufacturing the “antigens” which are at the core of immunoassays that establish exposure or immunity to the Rubella virus, the cause of German Measles. This marks a milestone for Microbix shareholders, as product from subsequent bioreactor batches will more fully...

Appointment of Labquality Oy of Finland for 7 Countries MISSISSAUGA, April 27, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Labquality Oy (Labquality) as a distributor of its Quality Assessment Products (QAPs™) in seven (7) countries. Under an agreement between the parties, Labquality has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Denmark, Estonia, Finland, Latvia, Lithuania, Poland, and Sweden. As distributor, Labquality will...

Timing of Product Shipments Affects Results MISSISSAUGA, May 14, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, reports results for its second quarter and first half of fiscal 2020 (“Q2” and “H1”) ended March 31, 2020, with the timing of product shipments to customers affecting Q2 results. Management Discussion Q2 revenues were down 32% from 2019, which had achieved record results for a fiscal second quarter. The year-over-year decline was largely due to the timing of customer orders and delivery...

Appointment of D.I.D. S.p.A. of Milan for Italy MISSISSAUGA, May 12, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Diagnostic International Distribution S.p.A. of Milan (D.I.D.) as distributor of its Quality Assessment Products (QAPs™) for Italy. Under an agreement between the parties, D.I.D. has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Italy. As distributor, D.I.D. will provide marketing, inventorying, distribution, and...

Registration Enables Immediate Usage of SARS-CoV-2 Controls by U.S. Clinical Labs MISSISSAUGA, CANADA, May 7, 2020 – Microbix Biosystems In...

SARS-CoV-2 Controls for Canadian Labs in Swab and Vial Formats MISSISSAUGA, CANADA, May 6, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it has begun providing its REDx™FLOQ® SARS-CoV-2 swab-format and REDx™ SARS-CoV-2 vial format quality assessment products (QAPs™) as controls to clinical laboratories in Canada. A first commercial run of 4,000 units was split between the REDx™FLOQ® SARS-CoV-2 swab-format and REDx™ SARS CoV-2 vial-format, with positives and negatives of each format...

Appointment of R-Biopharm AG for 11 Countries MISSISSAUGA, May 15, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of R-Biopharm AG (R-Biopharm) as distributor of its Quality Assessment Products (QAPs™) in eleven (11) countries. Under an agreement between the parties, R-Biopharm has been appointed as distributor of Microbix’s quality assessment products (QAPs™) for Australia, Belgium, Canada, France, Germany, Luxembourg, Netherlands, New Zealand, Norway, Spain, and the United...

Presentation and Panel Participation at Adelaide Capital Event on April 23 MISSISSAUGA, CANADA, April 21, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces that it will be participating in the “Virtual COVID & Healthcare Mini Conference” being hosted by Adelaide Capital on April 23 from 12:00-5:00 PM ET. The conference will showcase the contributions that Canadian companies are making to help fight the coronavirus pandemic. Microbix will be discussing its longstanding work in providing the...

Enables Immediate Usage of SARS-CoV-2 Controls by Clinical Labs across Canada MISSISSAUGA, CANADA, April 21, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator and exporter, announces that it has attained medical devices establishment licensing from Health Canada, enabling the immediate usage of its quality assessment products (QAPs™) by clinical laboratories, including its QAPs to help ensure the accuracy of COVID-19 disease testing. At present, Microbix has capacity to make 5,000 units per week of room-temperature stable COVID-19...

https://www.mbot.com/news/cameron-groome-mississauga-company-contributes-covid-19-solution-podcast/

Laboratory External Quality Assessment, Proficiency Testing, & Accreditation MISSISSAUGA, ONTARIO and VANCOUVER, BC, CANADA, April 9, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®) and Oneworld Accuracy (1WA) announce a strategic collaboration to provide a global external quality assessment (EQA) program to support clinically-effective COVID-19 testing. Based in Canada, this program will be made available to all governments to underpin their public health responsibility to ensure accurate and reliable COVID-19 testing. In every country and more than...

TORONTO, April 2, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the voting results from the Annual and Special Meeting of Shareholders (the “Meeting”) that was held on March 28, 2018. At the Meeting, 42.78% of the issued and outstanding shares were represented. A majority of shareholders voted in favour of all resolutions brought before the Meeting. Details of all resolutions that were voted upon are set out in the Management Information Circular (the “Circular”) dated February 9, 2018. The...

Whole-genome QMS Support Tool on COPAN® FLOQSwabs® MISSISSAUGA, CANADA, March 30, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®) announces the creation, verification, and imminent commercial availability of a quality assessment product (QAP™) to help ensure the accuracy of COVID-19 disease testing. By creating this unique product, Microbix is contributing to the development of new methods and improved methods for SARS-CoV-2 virus (COVID-19) detection and is helping to improve the accuracy of existing protocols by providing reliable, whole-genome...

Remote Access to the AGM Provided to Avoid Physical Attendance MISSISSAUGA, March 25, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, provides an update about its Annual General Meeting (“AGM”).   The AGM will still be held on March 31, 2020 at 1:00 pm, however due to the closure of our planned venue and alternative venues, we will be proceeding with access being provided online or via...

Appointment of Alpha-Tec Systems, Inc. for the United States MISSISSAUGA, June 4, 2020 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator and exporter, announces the appointment of Alpha-Tec Systems, Inc. (Alpha-Tec), a Calibre Scientific Inc. firm, as distributor of its Quality Assessment Products (QAPs™) for the United States. Under an agreement between the parties, Alpha-Tec will provide physical distribution, sales and marketing, and technical support for the entire range of Microbix’s QAPs – including its whole-genome...

Customer Validation of New Manufacturing Process Completed TORONTO: September 13, 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, announces its first full-scale shipment of antigen produced using its new bioreactor manufacturing process, following customer validation. Microbix’ revenues are derived principally from the sales of its antigens for use in diagnostic tests. Historically, those antigens have been produced in thousands of “roller bottles,” a longstanding method of production that requires...

Positive Cash Flow from Operations Achieved MISSISSAUGA, February 13, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its first quarter of fiscal 2020 (“Q1”) ended December 31, 2019, with positive cash flow from operations (“CFO”) and seasonally weak sales. Management Discussion Microbix regularly has its weakest quarterly sales in its fiscal first quarters, due to their...

TORONTO, October 19, 2017 – Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), a developer and marketer of biological products and technologies, announces that it has completed a brokered private placement financing totaling $2.33 million dollars, resulting in the issue of 7,784,500 million units (“Units”) at a price of $0.30 per unit. Each Unit consists of one common share (“Common Share”) of Microbix and one-half of one warrant to purchase one Common Share. Each whole warrant (“Warrant”) entitles the holder to purchase one additional Common...

Full-Year Sales of $13.4 Million, Progress Toward Sustained Profitability MISSISSAUGA, December 20, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, reports results for its fiscal year (“2019”) and fourth quarter (“Q4”) ended September 30, 2019, with stronger sales and progress toward its operational goals. Management Discussion In 2019, Microbix advanced upon its goal of sustained...

IVD Controls Data at EUROGIN, December 4-7, 2019 MISSISSAUGA, December 2, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces it has been invited to present the performance of its in-vitro diagnostics (IVD) quality products “IVD Controls” at EUROGIN 2019, the annual congress of the European Research Organization on Genital Infection & Neoplasia. At EUROGIN, Microbix will be...

2019 “OBAA” for Excellence in Export Strategy MISSISSAUGA, November 18, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices (QAPs™) that help ensure test accuracy, announces it has been awarded the “Beyond Borders” Ontario Business Achievement Award (OBAA) for 2019 by the Ontario Chamber of Commerce (OCC). The award was presented at the OCC OBAA gala the evening of November 14 and recognizes success in developing and...

Two Abstracts on IVD Controls at EMMD, October 9-11, 2019 Download PDF Download MS Word

Meetings with Growth-Oriented Investors, October 3, 2019 MISSISSAUGA, October 1, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and quality control medical devices, announces that it will be presenting to investors about Microbix at the StableView TECH19 conference, organized by StableView Asset Management and being held at the Arcadian Court event venue in Toronto, ON, October 3, 2019. Microbix’s CEO, Cameron Groome, will make a corporate presentation and, with COO Ken Hughes and CFO Jim Currie, will...

Meetings with Growth-Oriented Investors, September 27-29, 2019 MISSISSAUGA, September 25, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of clinical diagnostic materials and medical devices for test quality control, announces that it will be presenting to investors about Microbix at the Muskoka Capital Conference, organized by Capital Event Conferences and being held at the JW Marriott Rosseau Muskoka, in Minett, ON, September 27-29, 2019. Microbix’s CEO, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company...

Four IVD Controls to Support Performance of Human Papilloma Virus (HPV) Tests MISSISSAUGA, September 19, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, is pleased to announce U.S. availability of four innovative in-vitro diagnostic (IVD) control products for evaluating performance, procedures, and workflow of laboratory tests that detect and type HPV nucleic acids (DNA or RNA) in various human tissue samples. HPV is a family of more than 100 closely-related viruses, commonly described as “types,” of...

Four IVD Controls to Support Performance of Human Papilloma Virus (HPV) Tests MISSISSAUGA, September 5, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, is pleased to announce European registration for four innovative in-vitro diagnostic (IVD) control products for evaluating performance, procedures, and workflow of laboratory tests that detect and type HPV nucleic acids (DNA or RNA) in various human tissue samples. HPV is a family of more than 100 closely-related viruses, commonly described as “types,”...

Q3 Sales of $3.1 Million and $9.8 Million Year-To-Date TORONTO, August 12, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its third quarter and nine months of fiscal 2019, the three-month and nine-month periods ending June 30, 2019 (“Q3” & “YTD”), with record YTD sales, strong YTD sales growth, improving percentage gross margin, and progress on its strategic goals. Management Discussion Sales of $3.1 million for Q3 were down slightly vs. Q3 2018 and were to antigen customers...

Largest Customer Confirms Conversion Timetable & Provides Full-Scale Order TORONTO, August 1, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, provides an update on the conversion of its highest-selling product into bioreactors – that the largest customer for that antigen has confirmed its intended timetable for conversion of its future orders to bioreactor product and has provided its initial full-scale order. In 2018, Microbix completed a 500% expansion of its bioreactor capacity, moving to six...

Contribution of $2.75 Million to Scale-up, Meet Demand, and Create Highly-Skilled Jobs MISSISSAUGA, July 30, 2019 – Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, is pleased to announce the execution of a contribution agreement with the Federal Economic Development Agency for Southern Ontario (FedDev Ontario). Today, the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development, Minister responsible for FedDev Ontario, and Member of Parliament for Mississauga–Malton, announced a...

Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings TORONTO, May 13, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its second quarter and first half of fiscal 2019, the three-month and six-month periods ending March 31, 2019 (“Q2” & “H1”), with record sales, strong sales growth, improving percentage gross margin, materially positive net earnings, and progress on its strategic goals. Management Discussion Sales of $4.25 million for Q2 were very strong...

Healthcare Investment Conference in Toronto on May 2 & 3, 2018 TORONTO, April 30, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has been invited to present to investors about Microbix at the Bloom Burton & Co. Healthcare Investment Conference, being held at the Toronto Sheraton Centre Hotel on Wednesday and Thursday, May 2 and 3, 2018. Microbix’ CEO, Cameron Groome, will speak to its latest corporate presentation at 3:30 PM ET on Thursday, May 3, in Hall C of the conference....

Ken Hughes Appointed COO, Kathryn Froh Retiring TORONTO, April 18, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has appointed Dr. Kenneth (Ken) Hughes as its Chief Operating Officer (“COO”) and that Mrs. Kathryn Froh, its Vice President, Diagnostics is retiring from her full-time role, but will be remaining an employee and will be available to assist with special projects. Ken Hughes has been in the life sciences industry for more than 25 years and has worked as a CEO, senior...

TORONTO, March 28, 2019 - Microbix Biosystems Inc. (TSX: MBX, “Microbix” or the “Company”), an innovator of biological products and technol...

Using Shareholder-Approved Plan to Incentivize and Retain TORONTO, February 25, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces the issuance of stock options under its shareholder-approved 2018 stock option plan (the “Stock Option Plan”), as part of its compensation programs to incentivize and retain its board of directors, executives, and managers. Details of the Option Issuance In...

Lower Sales, Improving Gross Margin, Positive Cash Flow from Operations TORONTO, February 12, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its first quarter of fiscal 2019, the three-month period ending December 31, 2018 (“Q1”), with lower sales, improving percentage gross margin, improving and positive cash flow from operations and progress toward its operational goals. Management Discussion Sales for Q1 were held back by a combination of delayed shipment of a viral antigen...

New Customers, More Products, and Expanding Capacity TORONTO, February 5, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, provides an update on the expansion of its quality assessment product lines, announcing the addition of new customers, more products, and steps to expand its production capacity. Microbix’s quality assessment products (QAPs™) are stabilized and inactivated pathogen samples. QAPs are used by proficiency organizations, diagnostic test developers, researchers and clinical laboratories...

ISO 13485:2016 Medical Devices Certification Attained TORONTO, December 24, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has attained the ISO 13485:2016 Medical Devices certification – an enhancement to its quality management system that is expected to accelerate the growth of its QAPs™ lines of quality assessment products. Microbix has operated under the ISO 9001:2015 general quality standard or its predecessors since 2009, manufacturing its antigen products under that system....

Full-Year Sales Growth of 23%, Progress Toward Sustained Profitability TORONTO, December 21, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports results for its fourth quarter of fiscal 2018, the three-month period ending September 30, 2018 (“Q4”), with strong sales and progress toward its operational goals. Management Discussion In 2018, Microbix advanced upon its goal of sustained profitability, tripling its prior rate of sales growth, increasing its manufacturing capacity, and undertaking...

Recognized with 2018 Business Innovation Award by MBOT TORONTO, November 19, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it has been recognized with the 2018 Business Innovation Award by the Mississauga Board of Trade (MBOT). The award was provided to Microbix at the MBOT Business Awards of Excellence event the evening of November 15. The 2018 Business Innovation Award was in recognition of Microbix’s innovations in making native antigens and quality assessment products, its...

Showcasing Antigen and Quality Assessment Products TORONTO, November 6, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be exhibiting its antigens and quality assessment products at MEDICA, a leading international trade fair for the medical sector. The 2018 MEDICA fair is being held at the Messe Dusseldorf exhibition grounds in Dusseldorf, Germany from November 12 to 15, 2018. At MEDICA, Microbix will showcase its industry-leading line of native antigen products and its new...

Conference Introduces Growth Companies to Investors, September 28-30, 2018 TORONTO, September 27, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be presenting to investors about Microbix at the Muskoka Capital Conference, organized by Capital Event Conferences and being held at the JW Marriott Rosseau Muskoka, in Minett, Ontario from September 28-30, 2018. Microbix’ CEO, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company investors during the...

Microbix Reports Record Third Quarter Sales Year-Over-Year Sales Growth of 24% in First Nine Months   TORONTO, August 14, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial results for its third quarter of fiscal 2018, the three-month period ending June 30, 2018 (“Q3”), with record sales and progress toward its operational goals. Third Quarter Financial Results Total Q3 revenue was $3,235,224, a 17% increase over 2017 third quarter revenue of $2,773,365.  Included were antigen and...

Showcasing New Quality Assessment Products TORONTO, July 26, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be exhibiting its Quality Assessment Products (QAPs™) at the 70th annual clinical laboratory exposition of the American Association of Clinical Chemistry (AACC). The 2018 AACC exposition is being held at the McCormick Place convention center in Chicago, Illinois from July 31 to August 2, 2018. Microbix will be showcasing a series of its new PROCEEDx™ brand QAP products at...

Conference Introduces Growth Companies to Investors, July 12-14, 2018 TORONTO, July 12, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that it will be presenting to investors about Microbix at the Okanagan Capital Conference, organized by Capital Event Conferences and being held at the Delta Grand Okanagan hotel in Kelowna, B.C. from July 12 to 14, 2018. Microbix’ CEO, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company investors during the formal portion of...

Microbix Reports Record Second Quarter Sales

Production Capacity Increased to Support Growth Objectives TORONTO, May 8, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the completion of multiple upgrades to its production facility, to improve its revenue capacity and in support of corporate growth objectives. About Microbix’ Antigens & Quality Products Business Microbix is a leading independent producer of bacterial and viral antigens for use in medical diagnostics and laboratory quality assessment processes, selling over 100...

Healthcare Investor Conference in Toronto on April 30 & May 1 TORONTO, April 29, 2019 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces that its CEO, Cameron Groome, has been invited to present at the 2019 Bloom Burton & Co. Healthcare Investment Conference, being held at the Metro Toronto Convention Centre on April 30 and May 1. Microbix’ CEO will speak to its latest corporate presentation at 4:00 PM ET, on Tuesday, April 30 at the Metro Convention Centre, Conference Hall B.  Microbix’...

Torreya Partners to Assist with Kinlytic® urokinase TORONTO, April 26, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the engagement of Torreya Partners LLC of New York to assist it in reaching an agreement that enables the re-launch of its clot-buster drug, Kinlytic® urokinase,  into the United States market. About Kinlytic® urokinase Kinlyic® urokinase (formerly Abbokinase®) is an injectable thrombolytic or “clot-buster.” The drug is approved in the U.S. and Canada to clear blood clots and...

TORONTO, April 2, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces th...

TORONTO, February 14, 2018 ‐ Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial results for its first quarter of fiscal 2018, the three‐ month period ending December 31, 2017 (“Q1”), with record sales and improving margins and earnings. First Quarter Financial Results Total Q1 revenue was $2,885,567, an increase of 48% compared to the first quarter of fiscal 2017. Normalized to remove approximately $600,000 of revenues intended for Q4 that were delayed into Q1, year‐over‐year sales growth was...

Invited onto Panel about Managing Canadian Healthcare Companies for Growth TORONTO, January 29, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces its participation as a panelist and exhibitor at the Cantech Investment Conference, being held at the Metro Toronto Convention Centre on January 31, 2018. Celebrating its fifth anniversary, Cantech is Canada’s largest technology investment conference. Cantech works to connect approximately 3,500 engaged investors with over 100 leading...

  48 New Products Being Added, Under PTDx™ and PROCEEDx™ Brands TORONTO, January 18, 2018 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, announces the expansion of its quality assessment product family, with 48 new products being completed and made available for sale under its PTDx™ and PROCEEDx™ brands. Microbix’ quality assessment products are used by clinical laboratories, diagnostic test developers, researchers and proficiency organizations. Microbix has long offered a range of such products to...

TORONTO, December 21, 2017 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, reports financial results for its fiscal year and fourth quarter ended 30 September, 2017 (“2017” and “Q4”). Management Discussion In 2017, the Company achieved a number of notable milestones, including attaining record sales of over $10 million. Operational achievements included renewing and expanding agreements with key customers, validating the production of our highest-grossing product in a new, efficient bioreactor production platform,...

TORONTO, November 27, 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, confirms its production ramp-up, with a 500% increase in bioreactor capacity and other processing upgrades. Microbix’ revenues are mainly from sales of its antigens as critical components for makers of tests that diagnose infectious diseases. Antigens are traditionally produced in thousands of “roller bottles,” a method requiring considerable space, material and labour. Instead and in a significant advancement, Microbix has...

TORONTO, October 27, 2017 – Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), a developer and marketer of biological products and technologies, announces that it has completed a second and final tranche of the brokered private placement financing announced on October 19, 2017. An aggregate of 7,784,500 Units were issued in the first tranche for gross proceeds of $2.33 million. Microbix has now closed a second tranche of private placement financing for further gross proceeds of $1.17 million, resulting in the issue of 3,882,133 more Units at a...

TORONTO, October 19, 2017 – Microbix Biosystems Inc. (TSX: MBX) (“Microbix” or the “Company”), a developer and marketer of biological products and technologies, announces that it has completed a brokered private placement financing totaling $2.33 million dollars, resulting in the issue of 7,784,500 million units (“Units”) at a price of $0.30 per unit. Each Unit consists of one common share (“Common Share”) of Microbix and one-half of one warrant to purchase one Common Share. Each whole warrant (“Warrant”) entitles the holder to purchase one additional Common...

OCTOBER 11, 2017 TORONTO, October 11, 2017 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, is pleased to announce the withdrawal of legal claims alleging patent infringement that were filed in Canadian Federal Court against Microbix by ZeptoMetrix Corporation in October, 2016. The allegations by ZeptoMetrix have been withdrawn, following a settlement reached by the two companies. The withdrawal of the lawsuit is “with prejudice,” meaning that these allegations cannot be reasserted in Federal Court by ZeptoMetrix in...

Customer Validation Of New Manufacturing Process Completed TORONTO: September 13, 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, announces its first full-scale shipment of antigen produced using its new bioreactor manufacturing process, following customer validation. Microbix’ revenues are derived principally from the sales of its antigens for use in diagnostic tests. Historically, those antigens have been produced in thousands of “roller bottles,” a longstanding method of production that requires...

TORONTO August 24 2017 – Microbix Biosystems Inc. (TSX: MBX), a developer and marketer of biological products and technologies, announces it has applied to the TSX to amend the terms of 1,500,000 common share purchase warrants (the “Warrants”) issued in connection with a non-brokered private placement and held by one of its independent directors. The Warrants were issued in relation to a non-brokered private placement of units comprised of one common share and a common share purchase warrant, completed on August 21, 2014. Each Warrant currently entitles the...

TORONTO, August 14, 2017 – Microbix Biosystems Inc. (TSX: MBX), an innovator of biological products and technologies, today reports financial results for its fiscal third quarter and nine months ended June 30, 2017 (“Q3” and “9 Mo.”). Third Quarter Financial Results Total Q3 revenue was $2,773,365, an increase of 23% compared to the same quarter of fiscal 2016. Most revenues were derived from sales of antigen products, which are principally used in the manufacture of diagnostic tests for infectious diseases. Growth was driven by increased antigen orders from...